AutoGenomics Launches a Test for Genotyping Hepatitis C Virus on Its Microarray-Based INFINITI® Systems
Summary
Vista, CA, April 30, 2015 --( The assay is designed to individually detect 6 HCV genotypes (1-6) and 2 subtypes - 1a and 1b in a single test using AutoGenomics’ proprietary multiplexing microarray technology.With the discovery of genes and their link to various disease states the platform has the versatility to revolutionize the way patients are diagnosed, monitored and managed, leading to the era of precision medicine.AutoGenomics intends to apply to the US Food and Drug Administration for premarket approval for the test.According to World Health Organization estimates, up to 150 million people have chronic HCV infections.2, 3“We are making this assay available on our INFINITI® Plus and INFINITI® High Throughput System to reach low, medium and high volume testing sites,” said Fareed Kureshy, President and Chief Executive Officer of AutoGenomics.About AutoGenomicsAutoGenomics Inc., a privately held company based in Vista, CA, has developed the first automated, microarray based multiplexing diagnostic platform that can be used to assess disease signatures with novel genomic and proteomic markers in the area of pharmacogenomics, genetic disorders, infectious disease and cancer.With the discovery of genes and their link to various disease states the platform has the versatility to revolutionize the way patients are diagnosed, monitored and managed, leading to the era of precision medicine.